HEPCFIX ( DACLATASVIR) IS A NS5A REPLICATION COMPLEX INHIBITOR. Hepcfix ( Daclatasvir) is specifically indicated for use with sofosbuvir for the
treatment of patients with chronic hepatitis C virus (HCV) of genotype 1, 3, or 4
The other medications used in combination include sofosbuvir, ribavirin, and interferon, vary depending on the virus type and whether the person has cirrhosis. Hepcfix ( Daclatasvir)stops HCV viral RNA replication and protein translation by directly inhibiting HCV protein NS5A.
It is taken by mouth once a day. The recommended dose is 60 mg taken orally once daily with or without food in combination with sofosbuvir. The recommended treatment duration is 12 weeks. Dose modification: reduce dosage to 30 mg once daily with strong CYP3A inhibitors and increase dosage to 90 mg once daily with moderate CYP3A inducers.
Some common drugs that are strong CYP3A inducers include dexamethasone, phenytoin, carbamazepine, rifampin and St. John's Wort. Hepcfix ( Daclatasvir) is a CYP3A and p-glycoprotein substrate, therefore, drugs that are strong inducers or inhibitors of these enzyme will interfere with daclatascir levels in the body.
Dose modifications are made with concomitant use of daclatasvir and drugs that affect CYP3A or p-gp. When taking daclatasvir with non-nucleoside reverse transcriptase inhibitors, the dose of daclatasvir is increased to overcome CYP3A induction.
The dose for daclatasvir should be lowered when taking with antifungals, such as ketoconazole. Currently, there are no required dosage adjustments with concurrent use of daclatasvir and immunosuppressants, narcotic analgesics, antidepressants, sedatives, and cardiovascular agents.
It should not be used with St. John's wort, rifampin, or carbamazepine. It works by inhibiting the HCV protein NS5A. It is on the World Health Organization's List of Essential Medicines.
Portion 'A' First Floor,
Old No. 131, New No. 50,
Pedariyar Koil Street,
Seven Wells, Chennai - 600001.